Nachrichten |
| Datum / Uhrzeit |
Titel |
Bewertung |
| 21.05.26 13:21:00 |
Marktanalysebericht über spätstadiumchronische Nierenkrankheit bis 2036, Profil von Schlüsselspielern - Novartis, Merck & Co, Pfizer, Sanofi und Johnson & Johnson |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Der Markt für spätstadiumchronische Nierenkrankheiten (CKD) wächst rasant, getrieben durch die steigende globale Prävalenz von Diabetes, Hypertonie und dem Alterungsprozess. Fortschritte in Dialyse-Technologien, wie portablen und hausbasierten Systemen, sowie der Integration von Telemedizin, verbessern die Patientenversorgung und -adherence. Emerging-Märkte wie Asien-Pazifik und Lateinamerika bieten erhebliche Wachstumsmöglichkeiten, trotz Herausforderungen wie hohen Kosten und begrenztem Zugang in ländlichen Gebieten. |
| 23.04.26 19:07:24 |
How The Fresenius SE KGaA (XTRA:FRE) Investment Story Is Evolving With Mixed Analyst Targets |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
The fair value estimate for Fresenius SE KGaA was trimmed slightly from €55.90 to €55.47 per share, a modest adjustment of about €0.43. This shift lines up with Street research that combines higher targets from bullish houses and €1 to €2 cuts from more cautious analysts, leaving the overall picture more balanced than before. As you read on, you will see how these different calls shape the evolving narrative around risk, reward, and what to watch next.
Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Fresenius SE KGaA.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
JPMorgan lifted its Fresenius SE price target from €53.60 to €56.60 and kept an Overweight rating, signalling confidence that the current share price still leaves room relative to its fundamental valuation work. Deutsche Bank moved its target up from €56 to €57 while maintaining a Buy stance, pointing investors to what it views as an attractive risk and reward trade off if the company continues to execute on its plans. Morgan Stanley previously raised its target from €56 to €58, and Citi also applied a €5 upward adjustment, both moves highlighting support from large global houses for Fresenius SE's long term positioning.
🐻 Bearish Takeaways
Morgan Stanley has also trimmed its Fresenius SE target by €2 in a later update and by €1 in a separate report, a reminder that some analysts see execution risks and are more cautious on how much upside is already reflected in the current valuation.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!XTRA:FRE 1-Year Stock Price Chart
We've flagged 2 risks for Fresenius SE KGaA. See which could impact your investment.
What's in the News
Fresenius SE & Co. KGaA announced an annual dividend of €1.05 per share, with an ex dividend date on May 25, 2026, record date on May 26, 2026, and payment scheduled for May 27, 2026. The company plans to propose a dividend of €1.05 per share, corresponding to a payout ratio of 37% of core net income. The indicated payout ratio of 37% is in the upper half of the 30% to 40% core net income payout range set out in the Fresenius Financial Framework.
How This Changes the Fair Value For Fresenius SE KGaA
Fair value moved from €55.90 to €55.47 per share, an adjustment of about €0.43. Revenue growth in the model was revised from 4.49% to 4.40%. The net profit margin assumption was increased from 8.59% to 8.76%. The future P/E multiple was adjusted from 16.30x to 15.92x. The discount rate was kept unchanged at 5.114%.
Story Continues
Never Miss an Update: Follow The Narrative
Narratives link a company's real world story to a financial forecast and fair value. This makes it easier to see how business developments connect to the numbers. They refresh as new data, research, and risks come through.
Head over to the Simply Wall St Community and follow the Narrative on Fresenius SE KGaA to stay up to date on:
How rising demand from an aging population and chronic diseases feeds into Fresenius SE KGaA's hospital and dialysis businesses. What portfolio reshaping, biosimilar expansion, and digital health tools could mean for future margins and earnings stability. Key pressure points such as cost inflation, tighter healthcare budgets, and biosimilar competition that could challenge this outlook.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include FRE.DE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments |
| 21.04.26 14:45:18 |
Quest Diagnostics Q1 Earnings Call Highlights |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Quest Diagnostics logo
Key Points
Strong Q1 results and upgraded 2026 outlook: Q1 revenue was $2.9 billion (up 9.2% YoY) and adjusted EPS was $2.50 (about +13%), leading Quest to raise its 2026 guidance to $11.78–11.90 billion in revenue and $10.63–10.83 in adjusted EPS, with cash from operations ~ $1.75 billion and capex ~ $550 million. Volume growth driven by major collaborations: Total requisitions rose 10.9% (organic +10.8%), with Fresenius Medical Care and Corewell Health accounting for roughly 7 percentage points of organic volume (Corewell ~ $250M and Fresenius ~ $80–100M expected revenue contribution), while revenue per requisition fell 1.3% overall due to mix but rose ~2.5% excluding those collaborations. Productivity, AI and advanced diagnostics momentum with near-term costs: Quest is driving productivity through its Invigorate program and AI (40% customer-service productivity gain; Quest AI Companion ~350k engagements) and saw double-digit growth in advanced diagnostics (AD‑Detect more than doubled; Haystack MRD commercial ramp underway), though Project Nova and elevated fuel costs are expected to dilute ~ $0.25 of EPS in 2026 and trim roughly $0.05–$0.07 of EPS from fuel headwinds. Interested in Quest Diagnostics Incorporated? Here are five stocks we like better.
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Quest Diagnostics (NYSE:DGX) reported first-quarter 2026 results that management said reflected broad-based organic growth, improving productivity from automation and artificial intelligence, and contributions from major collaborations including Fresenius Medical Care and Corewell Health. The company also raised its full-year revenue and earnings guidance following the quarter.
First-quarter results and raised 2026 outlook
Chairman, President and CEO Jim Davis said Quest delivered “strong first quarter performance” as demand increased for clinical innovations, expansions into new clinical areas, and collaborations with healthcare and consumer health organizations. Davis said revenue grew more than 9% “almost entirely from organic revenue growth,” while adjusted diluted EPS rose about 13%.
→ $39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent Inflation
LifeMD Shares Come Back to Life on GLP-1 Business Growth
CFO Sam Samad reported consolidated revenue of $2.9 billion, up 9.2% year over year, with consolidated organic revenue up 9%.
Diagnostic Information Services revenue increased 9.4% versus the prior year, which Samad attributed to strong organic growth across physician, hospital and consumer channels. Reported operating income was $399 million, or 13.8% of revenue, compared with $346 million, or 13% of revenue, a year earlier. On an adjusted basis, operating income was $447 million, or 15.4% of revenue, compared with $406 million, or 15.3% of revenue, last year.
Story Continues
→ Could These 3 New-to-Market Quantum Computing Firms Threaten D-Wave?
Exact Sciences Serves Investors Exactly What They Wished For
Quest posted reported EPS of $2.24 compared with $1.94 a year ago; adjusted EPS was $2.50 compared with $2.21. Samad said adjusted EPS growth was driven largely by organic revenue growth, increased productivity, and lower interest expense, partially offset by wage increases and weather impacts.
Cash from operations was $278 million, down from $314 million in the prior-year period due to timing of receipts and disbursements and higher bonus payments, partially offset by higher operating income.
→ Nebius Group Is Trading Near All-Time Highs, Here's How Far It Has Come
Based on first-quarter performance, Samad said Quest raised its full-year 2026 guidance and now expects:
Revenue: $11.78 billion to $11.9 billion (6.8% to 7.8% growth) Reported EPS: $9.58 to $9.78 Adjusted EPS: $10.63 to $10.83 Cash from operations: approximately $1.75 billion Capital expenditures: approximately $550 million
Samad said the revenue guide does not include contributions from prospective M&A and that operating margin is expected to expand versus the prior year.
Volume, mix, and the impact of Corewell and Fresenius
Total volume, measured by requisitions, increased 10.9% year over year, with organic volume up 10.8%. Samad said Fresenius Medical Care and Corewell Health contributed roughly 7% to organic volume growth in the quarter; excluding those relationships, organic volume growth was 3.8%.
Revenue per requisition declined 1.3% year over year, which Samad said reflected business mix from the Corewell and Fresenius collaborations, as those relationships include a greater proportion of routine tests. Excluding that mix impact, revenue per requisition increased about 2.5%. Samad said unit price reimbursement was “relatively flat,” and that the main driver of the higher revenue per requisition excluding the two collaborations was an increase in tests per requisition.
In response to a question about expectations for the rest of the year, Samad reiterated the company’s view of continued organic utilization growth and quantified the embedded revenue contribution from the two collaborations. He said Corewell was expected to contribute about $250 million to revenue growth for the year, with Fresenius adding roughly $80 million to $100 million on top of that.
Davis also pointed to test mix benefits, highlighting growth in consumer health partnerships and advanced testing panels, as well as continued strength in Alzheimer’s-related testing. He said Quest’s Alzheimer’s testing “more than doubled year-over-year.”
Channel performance: physician, hospital, and consumer
Davis said the physician channel produced high single-digit revenue growth, driven by demand for clinical innovations, geographic expansion tied to greater health plan access, and increased enterprise account volume. He also highlighted growth in end-stage renal disease testing, describing it as a new clinical area for Quest and noting volume from dialysis clinics operated by Fresenius Medical Care, as well as independent dialysis clinics and other providers for lab and water purity testing.
In the hospital channel, Davis said revenue rose at a double-digit rate, with most of the growth coming from Quest’s collaborative lab solutions for Corewell Health. He said implementation was “proceeding smoothly” and that Quest was advancing its joint venture with plans to open a “state-of-the-art lab in Southeast Michigan next year.” Davis added that Quest’s pipeline for potential Co-Lab collaborations, as well as outreach and independent acquisitions, remained strong.
In consumer health, Davis said Quest again delivered “significant revenue growth” from both questhealth.com and consumer collaborations. He cited “robust double-digit customer repeat rates” on questhealth.com and demand for newer offerings such as the Elite Health Profile as well as autoimmune and hormone tests. He also said a meaningful part of growth came from consumers accessing Quest lab insights through apps and wearables of collaborators.
Discussing consumer partnerships, Davis said questhealth.com grew “somewhere between in the high 20s%,” while growth from partnerships and value-added resellers was even stronger. He also addressed Function Health’s acquisition of Getlabs, saying Quest viewed it as positive because it can expand access to home blood draws in areas where Quest has less patient service center coverage. Samad added that the collaboration ecosystem was broad-based, with growth coming from multiple players.
On profitability of consumer offerings, Samad said margins in these collaborations and on questhealth.com were “on par, if not slightly better than our overall enterprise average,” citing cash-pay dynamics and lower complexity from fewer denials and patient concessions.
Advanced diagnostics, AI, and operational initiatives
Davis said Quest delivered double-digit revenue growth across several advanced diagnostic areas during the quarter, including brain health, cardiometabolic and endocrine testing, and other categories. He reiterated momentum in the AD-Detect blood testing franchise for Alzheimer’s disease and described the company’s test menu and algorithmic approach, noting Quest developed a proprietary algorithm combining multiple biomarkers to establish Alzheimer’s pathology with sensitivity and specificity of 90% or greater.
In cardiometabolic and endocrine testing, Davis pointed to double-digit growth in parts of the portfolio, including Lp(a) and ApoB tests, as well as kidney, liver, and reproductive hormone testing. He noted new American Heart Association guidelines that recommend Lp(a) and ApoB testing for the first time and also recommend earlier cholesterol screening.
In oncology, Davis highlighted a research collaboration with City of Hope to study use of Quest’s Haystack MRD test in monitoring recurrence and treatment decisions in clinical trial participants across 14 U.S. sites. He also discussed an arrangement with Guardant Health related to blood collections for the Shield test, saying the partnership began during the quarter but it was “early” to comment on volumes.
Samad said Quest was making progress on Haystack’s commercial ramp and reimbursement, including submission to MolDX for technical assessment to pursue Medicare Advantage reimbursement, and noted the company had PLA codes priced at $3,900 baseline and $800 for monitoring. He said it was too early to discuss the year’s EPS phasing for Haystack and that Quest would provide updates over time.
On operations, Davis said Quest’s Invigorate program targets 3% annual cost savings and productivity improvements. He cited expanded deployment of AI and automation beyond the lab, including a 40% productivity boost among customer service agents using AI to triage and route emails. Davis also described the launch of Quest AI Companion in the myQuest app, powered by Google Gemini, saying patients engaged the tool about 350,000 times since rollout in the first quarter.
Davis also said Quest was scaling planning and design work for Project Nova, a multi-year initiative to transform order-to-cash processes and systems, with the first wave of solutions targeted for implementation in fall 2027.
Samad said Project Nova’s expected impact remained $0.25 of EPS dilution for the year, though expense cadence shifted, with more than 60% of costs now expected in the second half. He also cited elevated fuel costs as a headwind of $7 million to $10 million embedded in guidance, equating to about $0.05 to $0.07 of EPS.
Policy, reimbursement, and M&A commentary
On ACA subsidies and potential disenrollments, Davis said it was “too early to tell,” adding that Quest cannot identify every ACA-related requisition, though the company believed roughly 60% can be discretely identified and it was not seeing an impact to date. Samad said guidance still assumes a 30-basis-point revenue impact from ACA disenrollments, though the company had not seen the negative impact in the first quarter.
Regarding PAMA data collection and potential 2027 Medicare rates, Davis said Quest was prepared to submit data after May 1 and noted Medicare’s guidance that entities with more than $25,000 in Medicare revenue should submit, which he said could include more than 2,600 hospital labs. He said Quest would continue pushing for the RESULTS Act and described ongoing steps such as a CMS technical assessment and CBO scoring. Davis said it was too early to speculate on 2027 rates, but argued that broader participation in data submission could result in higher rates than reflected in prior, more limited submissions.
Davis also addressed investor concerns tied to the CMS CRUSH initiative, saying Quest did not believe it would have an impact. He said an OIG report identified 10 tests driving most of the 2024 Medicare lab spending increase, with seven being PLA codes in which Quest had “nothing,” and three being genetic or molecular-based tests where Quest’s exposure was “de minimis.”
On M&A, Davis said the “M&A funnel is good,” including health system outreach opportunities and some remaining independent labs. He said potential Medicare reimbursement changes were not affecting hospitals’ views of outreach, but argued health plans were increasingly scrutinizing the higher prices paid to some hospital labs versus independent labs and that Quest advocated for paying all labs the same for outreach work.
About Quest Diagnostics (NYSE:DGX)
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
The article "Quest Diagnostics Q1 Earnings Call Highlights" was originally published by MarketBeat.
View Comments |
| 09.04.26 12:00:00 |
CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg) |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Effective for Medicare claims beginning April 1, 2026
LAKE ZURICH, Ill., April 09, 2026--(BUSINESS WIRE)--Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for Medicare & Medicaid Services has issued indication-specific Healthcare Common Procedure Coding System (HCPCS) codes for Tyenne® (tocilizumab-aazg) for the treatment of COVID-19. The new codes will be effective for Medicare claims for eligible patients administered Tyenne on April 1, 2026.
These new COVID-19 HCPCS codes – Q0238 for injection, M0233 for intravenous infusion first-dose, and M0234 for intravenous infusion second-dose – will support billing and reimbursement for Tyenne when used in the treatment of COVID-19 in appropriate patients, consistent with its FDA-approved labeling.
"Fresenius Kabi’s indication-specific codes for COVID-19 represent an important step in supporting provider access and streamlined reimbursement for Tyenne," said Molly Benson, senior vice president, Biopharma, at Fresenius Kabi USA. "Clear coding helps facilitate efficient claims processing and reinforces our commitment to ensuring patients have access to important treatment options."
HCPCS codes are reimbursement codes used by healthcare providers and payers to process claims for drugs administered by injection, infusion, or other methods. These codes are used by Medicare, Medicaid, and commercial insurers to standardize claims submissions and reimbursement processes.
Tyenne previously received a permanent, product-specific Q-code for its approved autoimmune indications. These indication-specific COVID-19 codes further support appropriate coding and reimbursement pathways across care settings.
To learn more about how Fresenius Kabi provides comprehensive patient support, visit the KabiCare™ patient services hub. To learn more about Tyenne, please visit www.fresenius-kabi.com.
About Tyenne®, a tocilizumab biosimilar
Tyenne® (tocilizumab-aazg), a biosimilar to Actemra® (tocilizumab), is a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist. It was developed by Fresenius Kabi using advanced analytical and manufacturing technologies for use in the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving the product. Tyenne is contraindicated in patients with known hypersensitivity to tocilizumab products. For more information about Tyenne, please see the full prescribing information for the U.S. here, including Boxed Warning.
Story Continues
IMPORTANT SAFETY INFORMATION
RISK OF SERIOUS INFECTIONS
Patients treated with Tyenne® (tocilizumab-aazg) are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt Tyenne until the infection is controlled.
Reported infections include:
Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients, except those with COVID-19, should be tested for latent tuberculosis before Tyenne use and during therapy (except patients with COVID-19). Treatment for latent infection should be initiated prior to Tyenne use. Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Bacterial, viral and other infections due to opportunistic pathogens.
The risks and benefits of treatment with Tyenne should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Tyenne, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
CONTRAINDICATION
Tyenne is contraindicated in patients with known hypersensitivity to tocilizumab products.
WARNINGS AND PRECAUTIONS
COVID-19: Monitor for signs and symptoms of new infections during and after treatment with Tyenne in patients with COVID-19. Limited information is available regarding the use of Tyenne in patients with COVID-19 and concomitant serious active infections. The risks and benefits of treatment with Tyenne in patients with COVID-19 and other concurrent infections should be considered.
Gastrointestinal Perforations: Events of gastrointestinal (GI) perforation have been reported in clinical trials, primarily as complications of diverticulitis in RA patients. Use Tyenne with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with new-onset abdominal symptoms for early identification of GI perforation.
Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking intravenous or subcutaneous tocilizumab. Some of these cases have resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation. Most cases presented with marked elevations of transaminases (> 5 times ULN), and some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases.
Treatment with Tocilizumab was associated with a higher incidence of transaminase elevations; increased frequency and magnitude of these elevations were observed when tocilizumab was used in combination with potentially hepatotoxic drugs (e.g., methotrexate).
It is not recommended to initiate Tyenne treatment in RA, GCA, PJIA, and SJIA patients with elevated transaminases ALT or AST greater than 1.5x ULN. In patients who develop elevated ALT or AST greater than 5x ULN discontinue Tyenne.
Patients who are hospitalized with COVID-19 may have elevated AST or ALT levels. Multiorgan failure with involvement of the liver is recognized as a complication of severe COVID-19. The decision to administer Tyenne should balance the potential risks of acute treatment with Tyenne against the potential benefit of treating COVID-19. It is not recommended to initiate TYENNE treatment in COVID-19 patients with elevated ALT or AST above 10x ULN. Monitor ALT and AST during treatment.
Measure liver tests promptly in patients who report symptoms that may indicate liver injury. If the patient is found to have abnormal liver tests, Tyenne treatment should be interrupted. Tyenne should only be restarted in patients with another explanation for the liver test abnormalities after normalization of the liver tests.
Laboratory Parameters: Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Dosage modifications may be required.
Neutropenia: Treatment with tocilizumab products was associated with a higher incidence of neutropenia. It is not recommended to initiate Tyenne treatment in RA, GCA, PJIA, and SJIA patients with a low neutrophil count i.e., absolute neutrophil count (ANC) less than 2000 per mm3. In patients who develop an ANC less than 500 per mm3 treatment is not recommended.
It is not recommended to initiate Tyenne treatment in COVID-19 patients with an ANC less than 1000 per mm3. Neutrophils should be monitored.
Thrombocytopenia: Treatment with tocilizumab products was associated with a reduction in platelet counts. It is not recommended to initiate Tyenne in RA, GCA, PJIA, and SJIA patients with a platelet count below 100,000 per mm3. In patients who develop a platelet count less than 50,000 per mm3, treatment is not recommended.
It is not recommended to initiate Tyenne treatment in COVID-19 patients with a platelet count less than 50000 per mm3. Platelets should be monitored.
Elevated Liver Enzymes: It is not recommended to initiate Tyenne treatment in patients with elevated transaminases ALT or AST >1.5x ULN. In patients who develop elevated ALT or AST >5x ULN, treatment is not recommended.
Lipid Abnormalities: Treatment with tocilizumab products was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterols, and/or HDL cholesterol.
Immunosuppression: The impact of treatment with tocilizumab products on the development of malignancies is not known, but malignancies were observed in clinical studies with tocilizumab. Tyenne is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies.
Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis, have been reported in association with tocilizumab and anaphylactic events with a fatal outcome have been reported with intravenous infusion of Tocilizumab. Additionally, serious cutaneous reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported in patients with autoinflammatory conditions treated with Tocilizumab products. Tyenne for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis. For Tyenne subcutaneous injection, advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of Tyenne immediately and discontinue Tyenne permanently. Do not administer Tyenne to patients with known hypersensitivity to Tyenne.
Demyelinating Disorders: The impact of treatment with tocilizumab products on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies. Monitor patients for signs and symptoms of demyelinating disorders. Prescribers should exercise caution in considering the use of Tyenne in patients with preexisting or recent-onset demyelinating disorders.
Active Hepatic Disease and Hepatic Impairment: Treatment with Tyenne is not recommended in patients with active hepatic disease or hepatic impairment.
Vaccinations: Avoid use of live vaccines concurrently with Tyenne. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving Tyenne or on the effectiveness of vaccination in patients receiving Tyenne. Patients should be brought up to date on all recommended vaccinations prior to initiation of Tyenne therapy, if possible.
ADVERSE REACTIONS
Most common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions.
DRUG INTERACTIONS
In GCA patients, no effect of concomitant corticosteroid on tocilizumab exposure was Observed. Cytochrome P450s in the liver are down-regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in RA patients treated with Tyenne may restore CYP450 activities to higher levels than those in the absence of Tyenne leading to increased metabolism of drugs that are CYP450 substrates. Exercise caution when co-administering Tyenne with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, Etc.
USE IN PREGNANCY
The limited available data with tocilizumab products in pregnant women are not sufficient to determine whether there is a drug-associated risk for major birth defects and miscarriage, or other adverse maternal or fetal outcomes.
You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. You may also report side effects to Fresenius Kabi at (800) 551-7176.
INDICATIONS
Tyenne is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Tyenne is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Tyenne is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.
Tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
Tyenne is indicated for the treatment of chimeric antigen receptor (CAR)-T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older.
Tyenne is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Please see additional Important Safety Information in full Prescribing Information, including BOXED WARNING.
About Fresenius Kabi
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 41,000 employees and present in more than 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to essential medicines and technologies.
In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care.
Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare.
Fresenius Kabi is part of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale.
For more information, please visit www.fresenius-kabi.com/us. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn and Facebook.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409993943/en/
Contacts
Media contact
Joanie Clougherty (614) 717-5741
Joan.Clougherty@fresenius-kabi.com
View Comments |
| 13.03.26 18:31:43 |
Fresenius Medical Care AG (FMS) Looks to Improve Profitability After Smashing Q4 Expectations |
 |
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Fresenius Medical Care AG (NYSE:FMS) is among the best German stocks to buy according to analysts. On February 24, Fresenius Medical Care AG (NYSE:FMS) released its Q4 2025 results. The company posted EPS of €1.14, compared to €0.23 in the same quarter in 2024. It delivered revenue of €5.1 billion, flat from the year-ago quarter.Fresenius Medical Care AG (FMS) Looks to Improve Profitability After Smashing Q4 Expectations
yezry/Shutterstock.com
The management said the earnings numbers met internal targets, attributing this to efforts over the past three years that have focused on building a more resilient company. The management added that the achievements reflect a disciplined approach to operational and financial decisions.
Looking ahead, Fresenius Medical Care AG’s management spoke about further improving profitability, investing in the future, and overcoming regulatory headwinds. With this focus, the company is expecting 3% – 7% CAGR for operating income between 2025 and 2028. Additionally, the company aims to increase returns for shareholders.
In other news, Fresenius Medical Care AG has proposed a dividend of €1.49 per share based on 2025 earnings. The company said the proposed dividend is a 3% increase and represents a payout of about 33%. The company aims to maintain a stable dividend program at a payout ratio of 30% – 40%.
German healthcare company Fresenius Medical Care AG (NYSE:FMS) operates a network of 3,601 kidney dialysis clinics. These dialysis centers serve around 292,000 patients around the world. The company also provides dialysis machines.
While we acknowledge the potential of FMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments |
| 05.03.26 14:40:04 |
Hier ist, warum Fresenius (FMS) eine starke Wertaktie ist. |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
**Zusammenfassung:**
Dieser Text bewirbt einen kostenlosen Aktienanalysebericht von Zacks Investment Research. Es wird speziell ein Bericht mit "7 Besten Aktien für die nächsten 30 Tage" hervorgehoben, mit Fresenius Medical Care AG & Co. KGaA (FMS) als einer der Empfehlungen. Die Quelle des Berichts ist die Website Zacks Investment Research (zacks.com).
---
Would you like me to adjust the summary or translation in any way, or perhaps translate a different piece of text? |
| 03.03.26 11:34:49 |
Die Gesundheitsbranche muss sich einer neuen Weltordnung anpassen – Fresenius-Chef. |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Fresenius-CEO Michael Sen sagt, die Gesundheitsbranche müsse eine „neue Weltordnung“ analysieren und navigieren, in der der Handel transaktional und nationale Interessen im Vordergrund stehen. Er diskutierte die Auswirkungen geopolitischer Unsicherheiten auf die Geschäftstätigkeit seines Unternehmens in einem Interview mit Francine Lacqua auf Bloomberg’s „The Pulse“.
---
Would you like me to:
* Provide alternative translations?
* Expand on any specific part of the summary? |
| 01.03.26 11:08:36 |
Wie sieht\'s denn gerade aus bei der Bewertung von Fresenius SE KGaA, nachdem die letzten Zahlen da sind und die Aktio |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
Okay, here’s a summary of the text, followed by the German translation, staying within the 500-word limit:
**Summary (approx. 480 words)**
This article from Simply Wall St analyzes Fresenius SE KGaA (FRE), a German healthcare group, and suggests it’s currently undervalued by the market. Fresenius reported strong revenue (€22.4b) and net income (€1.1b), prompting investors to re-evaluate the company's valuation. However, recent share price declines (1 day: -0.8%, 7 days: -2.2%) contrast with a significant 1-year total shareholder return of 35.5%, indicating positive momentum.
The analysis highlights a potential intrinsic discount of around 58% and a 3-year total return exceeding 100%, raising the question of whether Fresenius’s price still reflects its true value. The narrative, focusing on Tokyo’s fair value assessment, estimates a fair value of €61.46 per share, significantly higher than the current market price of €50.90.
The article attributes this undervaluation to planned efficiency improvements under the new CEO, Michael Sen, aimed at streamlining the company after previous CEO Mark Schneider’s restructuring efforts. The narrative relies on specific long-term earnings assumptions to arrive at this fair value target.
However, significant risks remain. These include potential delays in achieving anticipated efficiency gains, and potential disappointment surrounding planned asset sales or restructuring terms.
Beyond the core narrative, the article contrasts Fresenius’s P/E ratio (26.2x) with those of its peers (21x) and the broader European healthcare sector (19.3x). This suggests the market may be overly cautious, potentially presenting a re-rating opportunity. The gap in P/E ratios could be seen as either a signal for increased valuation or as a limited buffer if investor sentiment shifts.
Simply Wall St recommends a proactive approach, encouraging readers to thoroughly investigate the company’s fundamentals and associated risks. They suggest exploring the Simply Wall St screener for related healthcare AI stocks, resilient stocks with low risk, high-quality undervalued stocks, and dividend fortresses.
The article emphasizes that the analysis is based on historical data and analyst forecasts, not financial advice. It clarifies that Simply Wall St holds no position in any of the stocks mentioned and aims to provide long-term focused analysis driven by fundamental data. The article acknowledges that the analysis might not factor in recent announcements or qualitative details.
---
**German Translation (approx. 510 words)**
**Zusammenfassung: Eine Analyse von Fresenius SE KGaA (XTRA:FRE)**
Dieser Artikel von Simply Wall St analysiert Fresenius SE KGaA (FRE), ein deutsches Gesundheitsunternehmen, und argumentiert, dass das Unternehmen derzeit vom Markt unterbewertet ist. Fresenius meldete starke Umsatzzahlen von 22,4 Milliarden Euro und einen Nettogewinn von 1,1 Milliarden Euro, was Investoren dazu veranlasst hat, die Bewertung des Unternehmens neu zu bewerten. Allerdings stehen kürzere Kursrückgänge (1 Tag: -0,8 %, 7 Tage: -2,2 %) im Gegensatz zu einer signifikanten Gesamtrendite für Aktionäre über ein Jahr von 35,5 %, was auf positive Dynamik hindeutet.
Die Analyse hebt einen potenziellen inneren Abschlag von etwa 58 % und eine 3-Jahres-Gesamtrendite, die 100 % übertrifft, hervor, was die Frage aufwirft, ob Fresenius’ Preis seinen wahren Wert noch widerspiegelt. Die Erzählung, die auf die Schätzung von Tokyo’s fairer Wert abzielt, schätzt einen fairen Wert von 61,46 Euro pro Aktie, deutlich höher als der aktuelle Markspreis von 50,90 Euro.
Das Unternehmen attribuiert diese Unterbewertung den geplanten Effizienzsteigerungen unter dem neuen CEO, Michael Sen, die darauf abzielen, das Unternehmen nach den Restrukturierungsbemühungen des vorherigen CEO, Mark Schneider, zu rationalisieren. Die Erzählung stützt sich auf spezifische langfristige Gewinnannahmen, um diese faire Wert-Zielsetzung zu erreichen.
Es bestehen jedoch erhebliche Risiken. Diese umfassen potenzielle Verzögerungen bei der Erreichung der erwarteten Effizienzsteigerungen, sowie potenzielle Enttäuschungen im Zusammenhang mit geplanten Vermögensverkäufen oder Restrukturierungsbedingungen.
Über die Kern-Erzählung hinaus stellt die Analyse von Fresenius’ P/E-Verhältnis (26,2x) im Vergleich zu denen seiner Wettbewerber (21x) und der breiteren europäischen Gesundheitsbranche (19,3x) dar. Dies deutet darauf hin, dass der Markt möglicherweise übermäßig vorsichtig ist und möglicherweise eine Umbewertungsmöglichkeit bietet. Die Differenz in den P/E-Verhältnissen könnte als Signal für eine Erhöhung der Bewertung oder als begrenzter Puffer interpretiert werden, wenn sich die Anlegerstimmung ändert.
Simply Wall St rät zu einem proaktiven Ansatz und fordert die Leser auf, die Fundamentaldaten des Unternehmens und die damit verbundenen Risiken gründlich zu prüfen. Sie empfehlen, den Simply Wall St Screener für verwandte Healthcare-AI-Aktien, widerstandsfähige Aktien mit geringem Risiko, hochwertige, unterbewertete Aktien und Dividendenfeststoffe zu nutzen.
Der Artikel betont, dass die Analyse auf historischen Daten und Analystenprognosen basiert und keine Finanzberatung darstellt. Es wird klargestellt, dass Simply Wall St keine Position in den genannten Aktien hält und darauf abzielt, langfristige Analysen basierend auf fundamentalen Daten zu liefern. Der Artikel räumt ein, dass die Analyse möglicherweise die neuesten Ankündigungen oder qualitativen Details nicht berücksichtigt. |
| 27.02.26 06:12:58 |
Pacira BioSciences Quartalsergebnisse Q4 – Wichtigste Punkte |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
**Zusammenfassung:**
Pacira BioSciences hat ein starkes Ende 2025 erlebt und deutliche Wachstum gezeigt und ihre Position im Markt für die akute Schmerzbehandlung gefestigt. Der Umsatz erreichte 726 Millionen Dollar, übertraf die Prognosen und demonstrierte den anhaltenden Erfolg seines Flaggschiffprodukts, EXPAREL. Mehrere Schlüsselfaktoren trieben diese Leistung voran, darunter der Einfluss des NOPAIN-Gesetzes, eine erweiterte Leistung von Zahlern und strategische Investitionen in geistiges Eigentum.
**Wesentliche Highlights:**
* **Umsatz & Wachstum:** Das Unternehmen erzielte 726 Millionen Dollar Umsatz für 2025, eine robuste Zahl, die Marktakzeptanz und eine kontinuierliche Ausführung der Vertriebsaktivitäten demonstrierte. Der Umsatz von EXPAREL im Q4 betrug 155,8 Millionen Dollar, was einem Volumenwachstum von etwa 7 % entspricht.
* **Aktienrückkauf:** Pacira führte 50 Millionen Dollar an Aktienrückkäufen durch, was ein Zeichen des Vertrauens in die Zukunft des Unternehmens ist und Kapital an die Aktionäre zurückgibt.
* **Führung für 2026:** Die Geschäftsleitung prognostizierte einen Umsatz zwischen 745 Millionen und 770 Millionen Dollar für 2026, wobei der Umsatz von EXPAREL voraussichtlich 600 bis 620 Millionen Dollar erreichen wird, gestützt auf starke Gewinnmargen von 77 bis 79 %.
* **Kommerzielles Wachstum:** Der Einfluss des NOPAIN-Gesetzes – die Reduzierung von Hindernissen für die nicht-opioidale Schmerzbehandlung – war ein wichtiger Katalysator. Die Anzahl der versicherten Personen erreichte etwa 102 Millionen am Jahresende (erweiterte sich auf 110 Millionen im frühen 2026) mit mehr als 7 % Wachstum im Volumen in seinen Top 5 Bundesstaaten, trotz Druck durch Preisnachlässe von Kaufgruppenorganisationen (GPOs).
* **Erweiterung des geistigen Eigentums:** Pacira stärkte sein Portfolio an geistigem Eigentum, erhöhte die Patentfamilien auf 21 und schloss eine bedeutende Vereinbarung mit LG Chem zur Kommerzialisierung in der Asien-Pazifik (APAC)-Region. Dies erweiterte ihren operativen Horizont bis 2039 aufgrund einer geschwindigkeitsbegrenzten Einigung mit Fresenius.
* **Pipeline:** Die Pipeline des Unternehmens geht mit vorläufigen Auswertungen für ZILRETTA und iovera sowie mit 52-Wochen-Daten für PCRX-201 voran – entscheidende Katalysatoren für zukünftiges Wachstum.
* **Margin Verbesserung:** Die Gewinnmargen verbesserten sich deutlich, erreichten im Q4 80 % aufgrund von verbesserten Herstellungseffizienzen und erhöhter Produktionsmenge. Das Unternehmen beabsichtigt, die Margen kontinuierlich zu verbessern, um das Ziel von 76 % bis 2030 zu erreichen.
* **Ausgaben:** Die Forschungs- und Entwicklungskosten (F&E) stiegen aufgrund der Lizenzvereinbarung mit AmacaThera und der laufenden Phase-2-Entwicklung von PCRX-201. Die Kosten für ZILRETTA und iovera° Registrierungsstudien stiegen ebenfalls. Die Kosten für Vertrieb, Verwaltung und Administration (SG&A) stiegen ebenfalls aufgrund unerwarteter Geschäftsentwicklungs- und Rechtsstreitkosten.
**Strategischer Fokus:**
Die Strategie von Pacira „5x30“ – das Ziel, 3 Millionen Patienten jährlich bis 2030 zu betreuen – ist weiterhin zentral für seinen Wachstumsplan. Das Unternehmen konzentriert sich auf die Erweiterung des Zugangs zu EXPAREL, die Vertiefung der Partnerschaften und die aggressive Verfolgung seiner Pipeline. |
| 25.02.26 19:03:18 |
Fresenius Jahresergebnisanruf 2025 – starke organische… |
|
|
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!**
**Zusammenfassung (ca. 500 Wörter)**
Fresenius SE & Co KGaA (FSNUY) präsentierte eine positive Prognose für 2025 und gab Ausblick für 2026, wobei starke organische Wachstumsraten und strategische Verbesserungen hervorgehoben wurden. Für 2025 prognostizierte das Unternehmen ein organisches Umsatzwachstum von 7 % und ein konstantes Währungswechsel-EBIT von 6 %, begleitet von einem doppelten Wachstum des Kern-EPS (16 % im 4. Quartal 2025). Seine Bilanz zeigt deutliche Verbesserungen, mit einem Verhältnis von Nettoverschuldung zu EBITDA von 2,7 – deutlich besser als die 3,7 von 2022. Es wurde eine Erhöhung der Dividende um 5 % auf 1,05 EUR pro Aktie angekündigt.
Insbesondere hob das Unternehmen die starke Leistung seiner Biopharma-Sparte hervor. Kabi erzielte im 4. Quartal 2025 ein organisches Wachstum von 10 %, während Helios im gleichen Zeitraum 8 % Wachstum verzeichnete, wobei die EBIT-Marge von Helios 11,7 % erreichte. Der operative Cashflow überstieg im 4. Quartal 2025 1,3 Milliarden EUR. Das Unternehmen verzeichnete eine Cash-Conversion-Rate von 1,1 % für das Jahr 2025.
Mit Blick auf 2026 erwartet Fresenius ein organisches Umsatzwachstum von 4-7 % und ein konstantes Währungswechsel-EPS von 5-10 %. Die EBIT-Marge von Kabi soll auf 16,5-17 % steigen, und die von Helios auf 10-10,5 %. Mehrere Herausforderungen und Unsicherheiten wurden jedoch anerkannt. Die makroökonomische Lage bleibt volatil, insbesondere aufgrund der Auswirkungen des Urteils des US-Obersten Gerichtshofs über Zölle. Die Leistung von Helios Deutschland liegt hinter den Erwartungen zurück, und die Behebung dieser Lücke ist eine Priorität für das Management im Jahr 2026. Das Unternehmen sieht zunehmenden Wettbewerb in seinem Biosimilars-Geschäft. Entscheidend ist, dass die Unternehmenskosten voraussichtlich steigen werden, was die Gewinnexpansionen bei Helios und Kabi negativ beeinflussen könnte.
Wichtige Erkenntnisse aus dem Telefonat ergaben, dass die flache Margenprognose für die Gruppe auf diese steigenden Unternehmenskosten – insbesondere auf Investitionen in Innovation und strategische Initiativen – zurückzuführen ist. Das starke Wachstum im 4. Quartal 2025 in der Biopharma-Sparte wurde teilweise durch eine vorübergehende Vertriebsvereinbarung beeinflusst. Das Management konzentriert sich auf strukturelle Produktivitätsverbesserungen und die Optimierung des Patientenflusses bei Helios Deutschland. Die Kapitalallokationsprioritäten für 2026 umfassen Investitionen in Forschung und Entwicklung, digitale Infrastruktur und sorgfältig geprüfte unorganische Investitionen, um das Portfolio zu stärken. Ein „Warning“-Signal von GuruFocus bezüglich potenzieller Bewertungsbedenken wurde ebenfalls hervorgehoben. |
